Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

International guidelines on access to biologic therapy: why the differences and which is best?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. National Institute for Health and Clinical Excellence (online 24 October 2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. []

  2. Fautrel B et al. (2007) Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 74: 627–637

    Article  CAS  Google Scholar 

  3. Hjardem E et al. (2005) Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 64: 1220–1223

    Article  CAS  Google Scholar 

  4. Sokka T et al. (2007) QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 66: 1491–1496

    Article  Google Scholar 

  5. National Institute for Health and Clinical Excellence (online April 2008) Abatacept for the treatment of rheumatoid arthritis. []

  6. Bansbeck NJ et al. (2005) The NICE re-appraisal of biologics in 2005: what rheumatologists need to know. Rheumatology 44: 3–4

    Article  Google Scholar 

  7. World Health Organization (online 17 September 2003) Technology appraisal programme of the National Institute of Clinical Excellence: a review by WHO. [ 17thseptember2003/item_tabled__world_health_organisation_report.jsp]

  8. Ikeda K et al. (2007) Aspects of early arthritis: biological therapy in early arthritis–overtreatment or the way to go? Arthritis Res Ther 9: 211

    Article  Google Scholar 

  9. Wolfe F et al. (2005) The Disease Activity Score is not suitable as a sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic. Arthritis Rheum 12: 3873–3879

    Article  Google Scholar 

  10. Deighton CM et al. (2006) Updating the BSR guidelines for anti-TNF therapy in adult RA (again). Rheumatology 45: 649–652

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Chris Deighton.

Ethics declarations

Competing interests

C Deighton works at the Department of Rheumatology at Derbyshire Royal Infirmary, which has received sponsorship from Abbott, Schering–Plough Pharmaceuticals and Wyeth for support of clinical meetings, and unrestricted grants from Schering–Plough and Wyeth to support an anti-tumor necrosis factor audit clerk and research nurse. C Deighton has also previously sat on an advisory board for Schering–Plough and received honoraria for talks at symposia sponsored by Abbott and Wyeth. K Hyrich declared no competing interests.

Supplementary information

Supplementary information

Examples of international guidelines on the use of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. (DOC 32 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Deighton, C., Hyrich, K. International guidelines on access to biologic therapy: why the differences and which is best?. Nat Rev Rheumatol 4, 520–521 (2008).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing